Frontiers in oncology · 2026
Prognostic significance of the C-reactive protein-to-lymphocyte ratio in patients with cancers.
СтатьяСистематический обзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liu Xiaohui, Zhang Shaobo, Liu Yi
Аннотация
BACKGROUND: The C-reactive protein-to-lymphocyte ratio (CLR), a novel inflammation-based biomarker, has been reported to be associated with prognosis in various cancers. However, the prognostic significance of CLR remains controversial. Therefore, we performed a meta-analysis to comprehensively evaluate the prognostic value of CLR in patients with cancers.
METHODS: Relevant studies were systematically searched in PubMed, Embase, and Web of Science up to March 21, 2026. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the association between CLR and survival outcomes, including overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS).
RESULTS: A total of 22 studies from 18 articles involving 7220 patients were included. The pooled analysis demonstrated that elevated CLR was significantly associated with poorer OS (HR:1.65, 95% CI: 1.43-1.91), PFS (HR:1.53, 95% CI: 1.15-2.05), and DFS (HR:1.67, 95% CI: 1.41-1.97). Subgroup analysis further confirmed the prognostic value of CLR across country, treatment method, sample size, cancer type and analysis type.
CONCLUSIONS: Elevated CLR was significantly associated with unfavorable survival outcomes in cancers and may serve as a promising prognostic biomarker in clinical practice.
METHODS: Relevant studies were systematically searched in PubMed, Embase, and Web of Science up to March 21, 2026. Pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the association between CLR and survival outcomes, including overall survival (OS), disease-free survival (DFS), and progression-free survival (PFS).
RESULTS: A total of 22 studies from 18 articles involving 7220 patients were included. The pooled analysis demonstrated that elevated CLR was significantly associated with poorer OS (HR:1.65, 95% CI: 1.43-1.91), PFS (HR:1.53, 95% CI: 1.15-2.05), and DFS (HR:1.67, 95% CI: 1.41-1.97). Subgroup analysis further confirmed the prognostic value of CLR across country, treatment method, sample size, cancer type and analysis type.
CONCLUSIONS: Elevated CLR was significantly associated with unfavorable survival outcomes in cancers and may serve as a promising prognostic biomarker in clinical practice.